Jiangsu Yahong Meditech Co., Ltd. (SHA:688176)

Market Cap	4.59B
Revenue (ttm)	201.56M
Net Income (ttm)	-384.06M
Shares Out	561.33M
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,989,671
Average Volume	8,326,935
Open	8.43
Previous Close	8.44
Day's Range	8.17 - 8.50
52-Week Range	4.71 - 8.74
Beta	0.67
RSI	51.95
Earnings Date	Apr 19, 2025

About Jiangsu Yahong Meditech

Jiangsu Yahong Meditech Co., Ltd. engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. Its pipeline includes APL-1202, an anti-tumor drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors and drug-resistant urinary tract infections; APL-1706, an agent drug, which is in Phase III cl...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 394
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688176

Financial Performance

In 2024, Jiangsu Yahong Meditech's revenue was 201.56 million, an increase of 1365.55% compared to the previous year's 13.75 million. Losses were -384.06 million, -4.09% less than in 2023.